帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍患者的临床效果分析
|
摘要
目的 观察帕罗西汀联合奥氮平对抑郁症合并睡眠障碍患者的临床效果。方法 2016年6月—2018年10月间用"随机分配法"将该院98例抑郁症合并睡眠障碍患者分为对照组和观察组两组,每组49例,其中对照组予以帕罗西汀治疗,观察组在对照组基础上联合奥氮平进行治疗,对比两组患者治疗前后的睡眠质量评分、临床疗效、临床观察指标和并发症发生情况。结果 观察组患者治疗后的睡眠质量(3.12±0.65)分明显优于对照组(5.48±0.71)分(t=17.162,P=0.001),临床总有效率(93.88%)要比对照组(73.47%)高(χ~2=7.470,P=0.006),睡眠潜伏期(0.35±0.72)h和清醒时间(1.13±0.92)h要比对照组短(3.14±0.06)h、(2.08±0.86)h(t=27.031、5.280,P<0.05),睡眠总时(6.54±2.56)h要长于对照组(3.06±1.89)h(t=7.655,P=0.001),觉醒次数(1.76±0.87)次要少于对照组(2.93±0.88)次(t=6.618,P=0.001),并发症总发生率6.12%要明显比对照组低20.41%(χ~2=4.348,P=0.037,P<0.05)。结论 对于抑郁症合并睡眠障碍患者进行帕罗西汀联合奥氮平治疗可有效提高临床疗效,改善睡眠质量与临床观察指标,减少不良反应的发生率,值得大力推广。
Objective To observe the clinical effect of paroxetine combined with olanzapine in patients with depression and sleep disor-ders. Methods A total of 98 patients with depression and sleep disorders in our hospital from June 2016 to October 2018 were divided into two groups: control group and observation group, including 49 cases in each group. The control group was treated with paroxetine.Based on the treatment of the control group, the observation group was treated with olanzapine. The sleep quality scores, clinical effi-cacy, clinical observations, and complications were compared between the two groups. Results The quality of sleep in the observation group(3.12±0.65)points was significantly better than that in the control group(5.48±0.71)points(t=17.162, P=0.001). The total clinical effective rate(93.88%) was better than that of the control group(73.47%)(χ~2=7.470, P=0.006). Sleep latency(0.35±0.72)h and awake time(1.13±0.92)h were shorter than those of the control group(3.14±0.06)h,(2.08±0.86)h(t=27.031, 5.280, P=0.001). The total sleep time(6.54±2.56)h was longer than the control group(3.06±1.89)h(t=7.655, P=0.001), And the number of awakenings(1.76±0.87 times) was less than that of the control(2.93±0.88) times(t= 6.618, P=0.001). The total incidence of complications(6.12%) was significantly lower than the control group 20.41%(χ~2=4.348, P=0.037,P<0.05). Conclusion Paroxetine combined with olanzapine in patients with depression and sleep disorders can effectively improve clinical efficacy, sleep quality and clinical observation indicators, and re-duce the incidence of adverse reactions, which is worthy of promotion.
Objective To observe the clinical effect of paroxetine combined with olanzapine in patients with depression and sleep disor-ders. Methods A total of 98 patients with depression and sleep disorders in our hospital from June 2016 to October 2018 were divided into two groups: control group and observation group, including 49 cases in each group. The control group was treated with paroxetine.Based on the treatment of the control group, the observation group was treated with olanzapine. The sleep quality scores, clinical effi-cacy, clinical observations, and complications were compared between the two groups. Results The quality of sleep in the observation group(3.12±0.65)points was significantly better than that in the control group(5.48±0.71)points(t=17.162, P=0.001). The total clinical effective rate(93.88%) was better than that of the control group(73.47%)(χ~2=7.470, P=0.006). Sleep latency(0.35±0.72)h and awake time(1.13±0.92)h were shorter than those of the control group(3.14±0.06)h,(2.08±0.86)h(t=27.031, 5.280, P=0.001). The total sleep time(6.54±2.56)h was longer than the control group(3.06±1.89)h(t=7.655, P=0.001), And the number of awakenings(1.76±0.87 times) was less than that of the control(2.93±0.88) times(t= 6.618, P=0.001). The total incidence of complications(6.12%) was significantly lower than the control group 20.41%(χ~2=4.348, P=0.037,P<0.05). Conclusion Paroxetine combined with olanzapine in patients with depression and sleep disorders can effectively improve clinical efficacy, sleep quality and clinical observation indicators, and re-duce the incidence of adverse reactions, which is worthy of promotion.
引文
[1]王丹.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍的临床疗效观察[J].转化医学电子杂志,2015,2(6):79-80.
[2]Pud D,Zlotnick C,Lawental E,et al.Pain depression and sleep disorders among methadone maintenance treatment patients[J].Addictive behaviors,2012,37(11):1205-1210.
[3]腾丽娟.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍疗效观察[J].河南医学研究,2016,25(8):1439-1440.
[4]饶晓红.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍患者的临床疗效[J].医疗装备,2018,31(20):145-146.
[5]庞春霞.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍100例[J].中国药业,2016,25(9):92-94.
[6]杨成超.观察帕罗西汀与奥氮平联合治疗抑郁症合并睡眠障碍患者的疗效及不良反应[J].中国药物经济学,2018,13(7):46-48.
[7]段能.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍临床效果观察[J].中国社区医师,2018,34(31):63-64.
[8]罗祝平,徐孟松,马迎春.帕罗西汀联合奥氮平治疗抑郁症并睡眠障碍效果观察[J].中国乡村医药,2018,25(20):11-12.
[9]孟祥军.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍的临床探讨[J].临床医药文献杂志:电子版,2018,5(16):163-164.
[10]赵丽丽,康晓辉,李现峰.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍的临床效果[J].保健医学研究与实践,2018,15(3):61-63.
[2]Pud D,Zlotnick C,Lawental E,et al.Pain depression and sleep disorders among methadone maintenance treatment patients[J].Addictive behaviors,2012,37(11):1205-1210.
[3]腾丽娟.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍疗效观察[J].河南医学研究,2016,25(8):1439-1440.
[4]饶晓红.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍患者的临床疗效[J].医疗装备,2018,31(20):145-146.
[5]庞春霞.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍100例[J].中国药业,2016,25(9):92-94.
[6]杨成超.观察帕罗西汀与奥氮平联合治疗抑郁症合并睡眠障碍患者的疗效及不良反应[J].中国药物经济学,2018,13(7):46-48.
[7]段能.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍临床效果观察[J].中国社区医师,2018,34(31):63-64.
[8]罗祝平,徐孟松,马迎春.帕罗西汀联合奥氮平治疗抑郁症并睡眠障碍效果观察[J].中国乡村医药,2018,25(20):11-12.
[9]孟祥军.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍的临床探讨[J].临床医药文献杂志:电子版,2018,5(16):163-164.
[10]赵丽丽,康晓辉,李现峰.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍的临床效果[J].保健医学研究与实践,2018,15(3):61-63.